Table 1 Patient characteristics
Flu–TBI | TLI-ATG | p value | |
|---|---|---|---|
Number of patients | 49 | 45 | |
Patient age, Median (range), years | 60 (38–73) | 59 (32–71) | 0.2 |
Patient gender (male/female), # of patients | 35/14 | 29/16 | 0.5 |
Donor type; # of patients | |||
HLA-identical sibling/10/10 HLA-allele matched URD | 29/20 | 25/20 | 0.8 |
Donor age, Median (range), years | 51 (19–66) | 46 (19–69) | 0.6 |
Female donor to male recipient, # of patients | 12 | 9 | 0.6 |
CMV-serostatus (donor/patient), # of patients | 0.3 | ||
−/− | 12 | 13† | |
−/+ | 17 | 12 | |
+/− | 8 | 3 | |
+/+ | 11* | 16 | |
Disease at transplantation; # of patients | |||
Acute myeloid leukemia | 17 | 16 | |
Acute lymphoblastic leukemia | 4 | 1 | |
Chronic lymphocytic leukemia | 7 | 3 | |
Myelodysplatic syndrome/ | 9 | 8 | |
Chronic myelomonocytic leukemia | 2 | 3 | |
Multiple myeloma | 3 | 2 | |
Myeloproliferative disorder | 2 | 1 | |
Non-Hodgkin lymphoma | 5 | 10 | |
Waldenström disease | 0 | 1 | |
Disease risk [17]: low/standard/high; # of patients | 15/24/10 | 12/18/15 | 0.4‡ |
Comorbidity (HCT-CI score) [18]; median (range) | 1 (0–8) | 0 (0–6) | 0.2 |
Performance status: 0/1/2; # of patients | 17/30/2 | 22/21/2 | 0.4 |
Prior autologous HCT; # of patients | 10 | 6 | 0.4 |
Graft composition (× 10 6 /kg recipient) | |||
CD34; median (range) | 5.6 (2.1–11.5) | 6.6 (2.4–11.8) | 0.02 |
CD3; median (range) | 334 (76–647) | 291 (73–834) | 0.8 |